Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial
Ronald Dahl, Peter M A Calverley, Antonio Anzueto, Norbert Metzdorf, Andy Fowler, Achim Mueller, Robert Wise, Daniel Dusser, Ronald Dahl, Peter M A Calverley, Antonio Anzueto, Norbert Metzdorf, Andy Fowler, Achim Mueller, Robert Wise, Daniel Dusser
Abstract
Objectives: This post hoc analysis of TIOtropium Safety and Performance In Respimat (TIOSPIR) evaluated safety and exacerbation efficacy in patients with stable (≥ 2 months) use of tiotropium HandiHaler 18 µg (HH18) prior to study entry, to evaluate whether there was a difference in risk for patients who switched from HH18 to tiotropium Respimat 2.5 µg (R2.5) or 5 g (R5).
Setting: TIOSPIR (n=17,135) was an international, Phase IIIb/IV, randomised, double-blind, parallel-group, event-driven trial.
Participants: Patients from TIOSPIR with chronic obstructive pulmonary disease (COPD) and postbronchodilator ratio of forced expiratory volume in 1 s to forced vital capacity ≤ 0.70, receiving HH18 before study entry, were analysed (n=2784).
Interventions: Patients were randomised to once-daily tiotropium R2.5 (n=914), R5 (n=918) or HH18 (n=952) for 2-3 years.
Primary outcomes: time to death (safety) and time to first COPD exacerbation (efficacy).
Secondary outcomes: number of exacerbations and time to first major adverse cardiovascular event (MACE).
Results: Baseline characteristics were similar in all groups. Respimat had a similar mortality risk versus HH18 (vital status follow-up, HR; 95% CI R2.5: 0.87; 0.64 to 1.17; R5: 0.79; 0.58 to 1.07) with no significant differences in the risk and rates of exacerbations and severe exacerbations across treatment groups. Risk of MACE and fatal MACE was similar for Respimat versus HH18 (HR; 95% CI MACE R2.5: 0.73; 0.47 to 1.15; R5: 0.69; 0.44 to 1.08; fatal MACE R2.5: 0.57; 0.27 to 1.19; R5: 0.67; 0.33 to 1.34). Overall risk of a fatal event (on treatment) was lower for R5 versus HH18 (HR; 95% CI R2.5: 0.78; 0.55 to 1.09; R5: 0.62; 0.43 to 0.89).
Conclusions: This analysis indicates that it is safe to switch patients from tiotropium HandiHaler to tiotropium Respimat, and that the efficacy is maintained over the switch.
Trial registration number: NCT01126437; Post-results.
Keywords: COPD; Efficacy; HandiHaler®; Respimat®; Switching; Tiotropium.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Figures
References
- Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2014.
- Boehringer Ingelheim. Summary of Product Characteristics: Spiriva 18 microgram inhalation powder, hard capsule 2013.
- Boehringer Ingelheim. Summary of Product Characteristics: Spiriva Respimat 2.5 micrograms solution for inhalation 2014.
- Hohlfeld JM, Sharma A, van Noord JA et al. . Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol 2014;54:405–14. 10.1002/jcph.215
- Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;7:CD009285 10.1002/14651858.CD009285.pub3
- Keating GM. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. Drugs 2012;72:273–300. 10.2165/11208620-000000000-00000
- Keating GM. Tiotropium Respimat® Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease. Drugs 2014;74:1801–16. 10.1007/s40265-014-0307-4
- Tashkin DP, Celli B, Senn S et al. . A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543–54. 10.1056/NEJMoa0805800
- Boehringer Ingelheim. Tiotropium (Spiriva) Respimat: evaluation of fatal events 2010.
- Dong YH, Lin HH, Shau WY et al. . Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 2013;68:48–56. 10.1136/thoraxjnl-2012-201926
- Loke YK, Singh S. Risks associated with tiotropium in chronic obstructive pulmonary disease: overview of the evidence to date. Ther Adv Drug Saf 2012;3:123–31. 10.1177/2042098612438388
- Mathioudakis AG, Chatzimavridou-Grigoriadou V, Evangelopoulou E et al. . Comparative mortality risk of tiotropium administered via HandiHaler or Respimat in COPD patients: are they equivalent? Pulm Pharmacol Ther 2014;28:91–7. 10.1016/j.pupt.2014.04.009
- Singh S, Loke YK, Enright PL et al. . Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011;342:d3215 10.1136/bmj.d3215
- Verhamme KM, Afonso A, Romio S et al. . Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD. Eur Respir J 2013;42:606–15. 10.1183/09031936.00005813
- Celli B, Decramer M, Kesten S et al. . Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:948–55. 10.1164/rccm.200906-0876OC
- Kesten S, Celli B, Decramer M et al. . Tiotropium HandiHaler in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis 2009;4:397–409. 10.2147/COPD.S4802
- Beasley R. Tiotropium Respimat increases the risk of mortality: pro. Eur Respir J 2013;42:584–9. 10.1183/09031936.00042113
- Wise RA, Anzueto A, Calverley P et al. . The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale. Respir Res 2013;14:40 10.1186/1465-9921-14-40
- Wise RA, Anzueto A, Cotton D et al. . Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013;369:1491–501. 10.1056/NEJMoa1303342
- Trotta F, Da Cas CR, Rajevic M et al. . Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study. BMJ Open 2015;5:e006619 10.1136/bmjopen-2014-006619
- Dahl R, Schmidt H, Koenen-Bergmann M et al. . Mixed treatment analysis comparing Tiotropium HandiHaler® and Respimat®. Poster (P-925) presented at ERS 2014, Munich, Germany.
- Hohlfeld JM, Furtwaengler A, Koenen-Bergmann M et al. . Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG Data From Four Randomized Clinical Trials. Int J Clin Pract 2015;69:72–80.
- Halpin D, Dahl R, Hallmann C et al. . Tiotropium HandiHaler® And Respimat®. COPD: a safety analysis on pooled data [Abstract]. Presented at ATS International Conference; 2014, San Diego, California, USA.
- Barnes NC, Jones PW, Davis KJ. Safety of tiotropium through the HandiHaler: why did meta-analyses and database studies appear to give a false alarm? Thorax 2014;69:598–9. 10.1136/thoraxjnl-2014-205155
- Tashkin DP, Metzdorf N, Hallman C et al. . Safety of tiotropium in renally impaired patients. Eur Respir J 2014;44:(Suppl 58), Abstract 923.
- Miravitlles M, Price D, Rabe KF et al. . Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2015;10:549–64. 10.2147/COPD.S71913
Source: PubMed